Compare HCA Health Inc (HCA) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs TG Therapeutics Inc — how do they compare? HCA Health Inc trades at $411.81 (market cap $89.08B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: HCA Health Inc is far larger — about 11.7× TG Therapeutics Inc's market cap, and HCA Health Inc pays a 0.76% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HCA | TGTX | |
|---|---|---|
Market Cap | $89.08B | $7.64B |
Sector | Health | Health |
52-Week High | $545.13 | $59.06 |
52-Week Low | $361.32 | $26.94 |
Enterprise Value | $139.62B | $7.84B |
Dividend Yield | 0.76% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare trades at $414.66, up 0.15% today, with a bullish technical signal from moving averages and a P/E of 13.8. Revenue grew to $75.60B in 2025, with net income of $6.78B, and the company has beaten EPS estimates for three consecutive quarters. Recent corporate actions include a $0.78 dividend scheduled for September 2026.
The outlook is positive with a consensus price target of $449.93, implying 8.5% upside, supported by strong earnings and institutional buy ratings. Risks include high debt levels, regulatory investigations, and expense pressures noted in Q2 2026 results. Investors should weigh solid fundamentals against legal and operational headwinds.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
